TrialInvestigational new drugs2015

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).

B B Y Ma et al.PubMed ↗Publisher ↗

No numbers read from the abstract.